Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Charles River Laboratories heads into its November 4 earnings date with a notable disconnect: short sellers have been building positions at their fastest pace in months, while Wall Street analysts have spent the past three weeks raising targets almost universally.
Short interest has accelerated sharply, nearly doubling over the past month. The share count borrowed rose 70% in 30 days to reach 6.5% of the free float, with a further 40% jump recorded in just the past week alone. The pace is striking: from roughly 1.9 million shares short in early September to 3.2 million today. Yet the lending market is telling a different story. Availability remains extremely loose at 753%, meaning there are more than seven shares available to borrow for every one already borrowed. Borrowing cost is just 0.54%, historically low. So shorts are piling in, but the borrow market is nowhere near stressed. There is no squeeze pressure embedded in current conditions. Options sentiment, meanwhile, is tilted toward calls. The put/call ratio is 0.41, well below its 20-day average of 0.47, and the z-score of negative 0.70 places it in mild call-heavy territory. Taken together, the positioning picture is split: short sellers are increasing conviction, but the derivatives market is not hedging for downside.
The analyst community has moved almost unanimously in the opposite direction from those shorts. Following a strong September 24 quarterly print (the stock jumped 5.6% on the day and added a further 3.4% over the following week), nearly every firm that covers the stock lifted its price target in the days afterward. Jefferies, Deutsche Bank, TD Cowen, Evercore, RBC, Barclays, and Baird all raised targets, nearly all maintaining Buy or Outperform ratings. UBS went further and reinstated coverage with a Buy and a $357 target. Most recently, Morgan Stanley's Ricky Goldwasser raised her target to $340 from $300 on October 13 while keeping an Overweight rating. The consensus mean target is $313, above the current $299 close. The bull case rests on durable outsourced drug development demand, a 1.19x DSA book-to-bill, a cost savings program worth more than $300 million, and management's stated 5% to 7% organic revenue growth target through 2030. The bear case centres on biopharma capital constraints reducing preclinical spend, ethical and regulatory pressure on non-human primate use, and execution risk around the K.F. acquisition. The analyst recommendation divergence factor scores in the 99th percentile of the ORTEX universe, an unusually clean sweep of bullish Street opinion. The EV/EBITDA multiple has edged down slightly over the past week and month to 15.4x, while the PE of 24x has moved a little higher over 30 days, a modest valuation expansion that has followed the stock's 7.5% one-month price gain.
On the ownership side, FMR (Fidelity) is the largest holder at 10.1% of shares, and recently increased its position by 626,000 shares as of September 30. Invesco added 636,000 shares over the same period, bringing its stake to 3.9%. T. Rowe Price added 380,000 shares. None of the 13D/G filings on record carry activist intent, all are passive Schedule 13G disclosures. The most notable net insider movement over the past 90 days is negative, with net sales of roughly 92,000 shares worth $26 million on a gross basis. Almost all of that activity was conducted under pre-arranged 10b5-1 plans, including the director James Foster's sizeable August exercise-and-sell sequence. The one exception worth noting is CFO Glenn Coleman's open-market purchase of 10 shares on September 30 at $297.43, a small but discretionary buy at a price close to current levels.
Retail attention has picked up relative to the stock's own 90-day history, with a Wikipedia view z-score of 1.1 as of late September, suggesting broader awareness around the time of the earnings beat. The ORTEX short score has climbed from around 38 in late September to 45.4 this week, its highest level in the recent window, consistent with the rising short position.
The next focal point is the November 4 earnings call, where the pace of short interest accumulation between now and then, and whether the lending market tightens to match it, will frame how charged the setup looks into the print.
See the live data behind this article on ORTEX.
Open CRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
